EGFR and head and neck squamous cell carcinoma: In this context Matsumoto et al. compared individual and dual targeting of EGFR and IGF-1R in an HNSCC xenograft model using the mAbs ganitumab (anti-IGF-1R) and panitumumab (anti-EGFR).